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Abstract  
Introduction: Superior vena cava (SVC) syndrome which is defined as the obstruction of blood flow through 
the SVC vein, often affecting patients with malignancy especially small cell lung cancer (SCLC) and is 
potentially an emergent condition needing prompt management. It is an ominous sign with poor prognosis 
and a mean of 8-10 months survival rate. 
Case presentation: Here we present a middle-aged man who presented with fascial swelling and dyspnea 
with final diagnosis of advanced SCLC. Combination of multiple chemotherapy regimen, prophylactic brain 
radiation with administration of anticoagulant drugs were performed for him leading toward extension of 
his survival to 28 months.  
Conclusion: These therapeutic approaches may lead to extending the survival in patients with SVC 
syndrome and SCLC. 
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INTRODUCTION
Superior vena cava (SVC) syndrome is defined as 
the obstruction of blood flow through the SVC vein 
(1). It is a kind of oncology emergency needing 
prompt management (2). Its symptoms such as 
fascial erythema, swelling and edema are 
secondary to upstream increase in venous 
pressure resulting from SVC vein occlusion 
leading to venous drainage impairment in the 
head and neck (3). It can potentially propel to 
cerebral edema and intracranial hypertension or 
airway compromise secondary to laryngeal edema 
(4). SVC syndrom usually affects patients with 
malignancy especially those with small cell lung 
cancer (SCLC) due to its central location and 
associated lymphadenopathy causing pressure 
effect over SVC vein (5). Although the underlying 
disease is somewhat sensitive to chemotherapy 
and radiotherapy, full recovery is often difficult to 
achieve. Here we present a middle-aged man who 
presented with SVC syndrome with final diagnosis 
of advanced SCLC who underwent several 
therapeutic methods leading toward extension of 
his survival to 28 months. 
CASE PRESENTATION 
A 54-year-old man presented with facial swelling, 
erythema and dyspnea lasting for 4 weeks. He also 
had productive cough with occasional bloody 
sputum. His past medical history was positive for 
25-year cigarette smoking (50 packs a year). On 
physical exam he was a man with body mass index 
(BMI) of 24 and blood pressure of 115/75 mmHg, 
heart rate of 85 beats per minute, respiratory rate 
of 19 per minute and O2 saturation of 90% on 
room air. Facial plethora, neck swelling, purple 
discoloration of the face and neck with prominent 
external jugular veins and some collateral vessels 
on his face, neck and upper thoracic area were 
found (Figure 1). Other parts of physical 
examinations were unremarkable. Chest X-ray 
was requested which showed lobulated 
mediastinal widening and “S-golden sign” in right 
lung representative of concomitant right hilar 
mass and upper lobe atelectasis. Elevation of the 
right hemi-diaphragm was also seen with 
“juxtaphrenic peak sign” secondary to upper lobe 
atelectasis (Figure 2). 
Contrast enhance computed tomography (CT) 
scan of the chest was performed which revealed a 
large mass about in right side of upper 
mediastinum extending to the right hilum. It 
causes significant narrowing and encasement of 
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the SVC vein and right pulmonary artery. 
Elevation of the right hemi diaphragm was 
demonstrated with linear atelectasis at basal 
segments of the right lung representative of 
phrenic nerve invasion by the mentioned large 
mass (Figure 3).  In visualized part of abdomen, 
there was enhancing heterogeneous mass 
involving the left adrenal gland suggestive of 
metastasis. Based on imaging findings advanced 
stage of lung cancer with metastasis (T4N2M1) 
was diagnosed.  
Trucut biopsy was done under guide of CT scan. 
The final histopathologic result confirmed SCLC. 
Chemotherapeutic regimen was prescribed 
including 14 cycle platinum doublets protocol, 
Cisplatin and Etoposide. SVC syndrome associated 
symptoms improved significantly after the third 
chemotherapy session.  
Ten sessions of the whole brain radiotherapy 
were done prophylactically. The patient had no 
neurological symptoms at time of brain radiation 
and subsequent brain magnetic resonance 
imaging (MRI) revealed no intracranial metastasis. 
Whole body positron emission tomography scan 
(PET-scan) was done to determine the response to 
treatment after the 8th chemotherapy. It showed a 
central 18 F-FDG avidly uptake mass in right 
upper lobe representative of primary SCLC (SUV 
max=8.3). Right para-tracheal 18 F-FDG-avidly 
uptake metastatic adenopathy was seen (SUV 
max=6.6). Another FDG avid uptake mass within 
the right adrenal gland was also note (SUV=6.2) 
(Figure 4). 
According to PET-scan no new metastasis was 
occurred and partial response to treatment was 
achieved. SVC syndrome symptoms reappeared 
after cessation of chemotherapy regimen. 
Chemotherapeutic regimen was changed to 
Ifosfamide – Etoposide therapeutic protocol. 
Intravenous anticoagulant medication was also 
prescribed. The patient’s syndrome responded 
well with new chemotherapeutic protocol. After 
that patient presented with bilateral pleural 
 
Figure 1: Neck and upper chest appearance of the patient. 
Engorgement and dilation of the superficial veins and 
extensive venous collateral circulation in the chest wall 
with also bilateral external jugular vein prominence and 




Figure 2: The chest x-ray of the patient. AP chest x-ray 
shows lobulated mediastinal widening and “S-golden sign” 
in right lung representative of concomitant right hilar mass 
and upper lobe atelectasis. (red arrow) elevation of right 
hemi-diaphragm is also seen (yellow arrow) with 




Figure 3: Axial contrast-enhanced computed tomography 
scan (CT scan) of upper mediastinum revealed large mass 
(green arrows) with pressure effect and encasement over 
compression of the SVC (red arrows) and extending to right 
hilum. 
 
ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2020;4(3):e79 Keshavarz et al 
   
 3 Copyright © 2020 Tehran University of Medical Sciences 
This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 License (CC BY-NC 4.0). 
 
 
effusion which pleurodesis with bleomycin was 
performed. After two years, the patient presented 
with neurologic symptoms including seizure and 
slurred speech. Subsequent brain MRI found 
multiple intracranial metastasis. Unfortunately, 
despite all therapeutic modalities, the patient was 
expired almost 28 months after initial 
presentation.  
DISCUSSION 
SVC syndrome usually presents in patients with 
underlying malignancy, leads to an ominous 
prognosis; but it sometimes responds to 
chemotherapy with or without radiotherapy (6, 
7). CT-scan is a valuable modality for detection of 
possible underlying malignancy in patients 
presenting with SVC syndrome (8).  
SCLC accounts for 20-25% of all lung cancer cases. 
Due to its central location and associated 
lymphadenopathy, causing pressure effect over 
SVC vein, it can cause SVC syndrome (5). It is an 
aggressive form of lung cancer with tendency 
toward dissemination and early metastasis (9). 
Limited-stage of SCLC is cured by combination of 
chemotherapy with radiation therapy; in about 
20% of the patient’s cure can be achievable in 
early stages. The mean survival rate for patients 
with limited-stage of the disease is nearly 18 
months (10). SCLC cases presenting at advanced 
stage of the disease are primarily treated with 
chemotherapy, with a high initial response rate of 
about 70% and a complete response rate of about 
30% but with a median survival time of 
approximately 10 months (11, 12).  
Nowadays platinum and etoposide combination is 
the accepted standard chemotherapeutic regimen 
(13). Thoracic radiotherapy (TRT) is another 
accepted therapeutic method for patients with 
limited stage of the disease (14). Adding TRT 
would improve the survival rate approximately 
5% in comparison to chemotherapy alone. TRT 
performed simultaneously with chemotherapy is 
more effective than sequential therapy (15). 
Furthermore, the survival benefit is greater if TRT 
is given earlier in the course of chemotherapy 
(16). Patients with SCLC whose symptoms persist 
or progress after first-line chemotherapy have a 
high mortality rate. Second-line therapy may 
produce a modest clinical benefit. Few studies 
have revealed that there is usually partial 
response to the SCLC after the first line of 
chemotherapy; but, unfortunately, we see the 
tumor regression infrequently, and most cases 
usually need second line therapy (17, 18).  
In a case report from the Netherland the authors 
reported a SCLC case with paraneoplastic 
nephrotic syndrome who had a 7-month survival 
rate. They present the same picture of our case 
(but they didn't start a prophylactic brain 
radiotherapy for the patient at all) and after 5 
months of first line chemotherapy, the patient had 
a brain metastases and then expired after two 
months (19); this is in contrast to our results 
about the survival rate. 
In another case from China, the authors presented 
a patient with transformed SCLC from lung 
adenocarcinoma with metastasis to the brain and 
then liver during the chemotherapy treatment 
cycles. They also did not do the prophylactic brain 
radiation in the first time that the diagnosis was 
confirmed, and finally they saw rapid progression 
of the tumor to other organs like brain and liver 
and the patient died within a short period of time 
(20).   
Although the combination of SVC syndrome and 
SCLC leads to survival rate of less than 8 months, 
here we report a case in which combination of 
multiple chemotherapy regimen, prophylactic 
brain radiation with administration of 
anticoagulant drugs contributed to the 
improvement of survival to 28 months. 
CONCLUSIONS 
Multiple combination of chemotherapeutic 
regimen with radiation therapy, prophylactic 
brain radiotherapy, and anticoagulant 
administration can leads to extending the survival 
in patients with SVC syndrome and SCLC, and may 
provide bright horizons in the treatment of similar 
patients. 
 
Figure 4: Frontal view of positron emission tomography 
scan (PET-Scan) showed an avidly uptake 18F-FDG mass 
lesion in the right upper lobe and the right para-tracheal 
that are primary lung mass and its metastatic para-tracheal 
lymph node respectively (red arrow) and another mass in 
the right adrenal gland (blue arrow) 
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